Objective:To determine the efficacy of losartan a specific angiotensin Ⅱ receptor antagonist

in improving renal function among renal transplant recipients with chronic allograft nephropathy(CAN).Methods:18 renal transplant recipients with CAN (group Ⅰ)were treated with losartan for at least one year.Another 23 patients with CAN (group Ⅱ) while not treated with losartan were used as control in the same period.Renal function

blood and urine TGF-β 1 concentration were compared between the two groups.Results:One year later

there were 12 patients (67.0%) with stabilized or improved graft function in group Ⅰ

and 4 patients (17.0%) in group Ⅱ.The difference was significant.Blood and urine TGF-β 1 concentration and renal function lost were lower m group Ⅰ than in group Ⅱ.No side effects were noted in all patients in group Ⅰ.Conclusion:Losartan can improve renal fimction among renal transplant recipients with chronic allograft nephropathy through reducing TGF-β 1 secretion in the kidney.